NCT03065959View on ClinicalTrials.gov

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

PHASE1TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

October 10, 2018

Study Completion Date

October 10, 2018

Conditions
Mobility Limitation
Interventions
DRUG

reldesemtiv

oral

DRUG

Placebo

oral

Trial Locations (5)

27157

Wake Forest University School of Medicine, Winston-Salem

32611

University of Florida, Gainesville

45701

Ohio University Heritage College, Athens

02111-1524

Tufts Medical Center, Boston

63110-1010

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Cytokinetics
All Listed Sponsors
collaborator

Cytokinetics

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT03065959 - A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility | Biotech Hunter | Biotech Hunter